Galectin Therapeutics
Pharmaceuticals, 87 Cambridgepark Dr, Norcross, Georgia, 02140, United States, 11-50 Employees
Phone Number: 16*********
Who is GALECTIN THERAPEUTICS
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on ...
Read More
-
Headquarters: 87 Cambridgepark Dr, Norcross, Georgia, 02140, United States
-
Date Founded: 2000
-
Employees: 11-50
-
Revenue: $1 Billion and Over
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from GALECTIN THERAPEUTICS
Galectin Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Galectin Therapeutics
Answer: Galectin Therapeutics's headquarters are located at 87 Cambridgepark Dr, Norcross, Georgia, 02140, United States
Answer: Galectin Therapeutics's phone number is 16*********
Answer: Galectin Therapeutics's official website is https://galectintherapeutics.com
Answer: Galectin Therapeutics's revenue is $1 Billion and Over
Answer: Galectin Therapeutics's SIC: 2834
Answer: Galectin Therapeutics's NAICS: 561110
Answer: Galectin Therapeutics has 11-50 employees
Answer: Galectin Therapeutics is in Pharmaceuticals
Answer: Galectin Therapeutics contact info: Phone number: 16********* Website: https://galectintherapeutics.com
Answer: Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Companys unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month